Skip to main content
Have a personal or library account? Click to login
Inter-observer variation in gross tumour volume delineation of oesophageal cancer on MR, CT and PET/CT Cover

Inter-observer variation in gross tumour volume delineation of oesophageal cancer on MR, CT and PET/CT

Open Access
|Oct 2024

References

  1. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2020: Estimated cancer incidence, mortality and prevalence worldwide in 2020. [internet]. [cited 2024 Jan 20]. Available at: http://globocan.iarc.fr/
  2. Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol 2020; 13: 1010–21. doi: 10.1007/s12328-020-01237-x
  3. Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D. ESMO Guidelines Working Group. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi51–6. doi: 10.1093/annonc/mdt342
  4. Eyck BM, Van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS Trial. J Clin Oncol 2021; 39: 1995–2004. doi: 10.1200/JCO.20.03614
  5. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074–84. doi: 10.1056/NEJMoa1112088
  6. Chan KKW, Saluja R, Santos KD, Lien K, Shah K, Cramarossa G, et al. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: a network meta-analysis. Int J Cancer 2018; 143: 430–37. doi: 10.1002/ijc.31312
  7. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007; 8: 545–53. doi: 10.1016/S1470-2045(07)70172-9
  8. Beaton L, Bandula S, Gaze MN, Sharma RA. How rapid advances in imaging are defining the future of precision radiation oncology. Br J Cancer 2019; 120: 779–90. doi: 10.1038/s41416-019-0412-y
  9. Sillah K, Williams LR, Laasch HU, Saleem A, Watkins G, Pritchard SA, et al. Computed tomography overestimation of esophageal tumor length: Implications for radiotherapy planning. World J Gastrointest Oncol 2010; 2: 197–204. doi: 10.4251/wjgo.v2.i4.197
  10. Decazes P, Hinault P, Veresezan O, Thureau S, Gouel P, Vera P. Trimodality PET/CT/MRI and radiotherapy: a mini-review. Front Oncol 2021; 10: 1–9. doi: 10.3389/fonc.2020.614008
  11. Lambrecht M, Haustermans K. Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiother Oncol 2010; 96: 339–46. doi: 10.1016/j.radonc.2010.07.019
  12. Lu J, Sun XD, Yang X, Ang XY, Qin Q, Zhu HC, et al. Impact of PET/CT on radiation treatment in patients with esophageal cancer: a systematic review. Crit Rev Oncol Hematol 2016; 107: 128–37. doi: 10.1016/j.critrevonc.2016.08.015
  13. Jiang C, Chen Y, Zhu Y, Xu Y. Systematic review and meta-analysis of the accuracy of 18F-FDG PET/CT for detection of regional lymph node metastasis in esophageal squamous cell carcinoma. J Thorac Dis 2018; 10: 6066–76. doi: 10.21037/jtd.2018.10.57
  14. Garcia B, Goodman KA, Cambridge L, Dunphy M, Wu AJ. Distribution of FDG-avid nodes in esophageal cancer: Implications for radiotherapy target delineation. Radiat Oncol 2016; 11: 1–8. doi: 10.1186/s13014-016-0731-6
  15. Machiels M, Wouterse SJ, Geijsen ED, van Os RM, Bennink RJ, van Laarhoven HW, et al. Distribution of lymph node metastases on FDG-PET/CT in inoperable or unresectable oesophageal cancer patients and the impact on target volume definition in radiation therapy. J Med Imaging Radiat Oncol 2016; 60: 520–27. doi: 10.1111/1754-9485.12474
  16. Münch S, Marr L, Feuerecker B, Dapper H, Braren R, Combs SE, et al. Impact of 18F-FDG-PET/CT on the identification of regional lymph node metastases and delineation of the primary tumor in esophageal squamous cell carcinoma patients. Strahlentherapie Onkol 2020; 196: 787–94. doi: 10.1007/s00066-020-01630-y
  17. Thomas L, Lapa C, Bundschuh RA, Polat B, Sonke JJ, Guckenberger M. Tumour delineation in oesophageal cancer – a prospective study of delineation in PET and CT with and without endoscopically placed clip markers. Radiother Oncol 2015; 116: 269–75. doi: 10.1016/j.radonc.2015.07.007
  18. Mamede M, El Fakhri G, Abreu-E-Lima P, Andler W, Nosé V, Gerbaudo VH. Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation. Ann Nucl Med 2007; 21: 553–62. doi: 10.1007/s12149-007-0040-0
  19. Han D, Yu J, Yu Y, Zhang G, Zhong X, Lu J, et al. Comparison of 18F-Fluorothymidine and 18F-Fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys 2010; 76: 1235–41. doi: 10.1016/j.ijrobp.2009.07.1681
  20. Zhong X, Yu J, Zhang B, Mu D, Zhang W, Li D, et al. Using 18F-Fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2009; 73: 136–41. doi: 10.1016/j.ijrobp.2008.04.015
  21. Nowee ME, Voncken FEM, Kotte ANTJ, Goense L, van Rossum PSN, van Lier ALHMW, et al. Gross tumour delineation on computed tomography and positron emission tomography-computed tomography in oesophageal cancer: a nationwide study. Clin Transl Radiat Oncol 2018; 14: 33–9. doi: 10.1016/j.ctro.2018.10.003
  22. Toya R, Matsuyama T, Saito T, Imuta M, Shiraishi S, Fukugawa Y, et al. Impact of hybrid FDG-PET/CT on gross tumor volume definition of cervical esophageal cancer: reducing interobserver variation. J Radiat Res 2019; 60: 348–52. doi: 10.1093/jrr/rrz004
  23. Vesprini D, Ung Y, Dinniwell R, Breen S, Cheung F, Grabarz D, et al. Improving observer variability in target delineation for gastro-oesophageal cancer – the role of 18Fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography. Clin Oncol 2008; 20: 631–38. doi: 10.1016/j.clon.2008.06.004
  24. Schreurs LM, Busz DM, Paardekooper GM, Beukema JC, Jager PL, Van der Jagt EJ, et al. Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability. Dis Esophagus 2010; 23: 493–501. doi: 10.1111/j.1442-2050.2009.01044.x
  25. Li F, Li Y, Wang X, Zhang Y, Liu X, Liu S, et al. Inter-observer and Intra-observer variability in gross tumor volume delineation of primary esophageal carcinomas based on different combinations of diagnostic multimodal images. Front Oncol 2022; 12: 1–10. doi: 10.3389/fonc.2022.817413
  26. Shi J, Li J, Li F, Zhang Y, Guo Y, Wang W, et al. Comparison of the gross target volumes based on diagnostic PET/CT for primary esophageal cancer. Front Oncol 2021; 11: 1–10. doi: 10.3389/fonc.2021.550100
  27. van Rossum PSN, Van Lier ALHMW, Lips IM, Meijer GJ, Reerink O, van Vulpen M, et al. Imaging of oesophageal cancer with FDG-PET/CT and MRI. Clin Radiol 2015; 70: 81–95. doi: 10.1016/j.crad.2014.07.017
  28. Hou DL, Shi GF, Gao XS, Asaumi J, Li XY, Liu H, et al. Improved longitudinal length accuracy of gross tumor volume delineation with diffusion weighted magnetic resonance imaging for esophageal squamous cell carcinoma. Radiat Oncol 2013; 8: 169. doi: 10.1186/1748-717X-8-169
  29. Vollenbrock SE, Nowee ME, Voncken FEM, Kotte ANTJ, Goense L, van Rossum PSN, et al. Gross tumor delineation in esophageal cancer on MRI compared with 18F-FDG-PET/CT. Adv Radiat Oncol 2019; 4: 596–604. doi: 10.1016/j.adro.2019.04.004
  30. Kouwenhoven E, Giezen M, Struikmans H. Measuring the similarity of target volume delineations independent of the number of observers. Phys Med Biol 2009; 54: 2863–73. doi: 10.1088/0031-9155/54/9/018
  31. Warfield SK, Zou KH, Wells WM. Simultaneous truth and performance level estimation (STAPLE): an algorithm for the validation of image segmentation. IEEE Trans Med Imaging 2004; 23: 903–21. doi: 10.1109/TMI.2004.828354
  32. Petrič P, Hudej R, Rogelj P, Blas M, Tanderup K, Fidarova E, et al. Uncertainties of target volume delineation in MRI guided adaptive brachytherapy of cervix cancer: a multi-institutional study. Radiother Oncol 2013; 107: 6–12. doi: 10.1016/j.radonc.2013.01.014
  33. Rogelj P, Hudej R, Petric P. Distance deviation measure of contouring variability. Radiol Oncol 2013; 47: 86–96. doi: 10.2478/raon-2013-0005
  34. Šegedin B. [Objective evaluation of the impact of learning on differences in the contouring of target volumes in radiotherapy]. [Slovenian]. Doctoral thesis. Ljubljana: University of Ljubljana. Medical Faculty; 2016.
  35. Machiels M, Jin P, van Hooft JE, Gurney-Champion OJ, Jelvehgaran P, Geijsen ED, et al. Reduced inter-observer and intra-observer delineation variation in esophageal cancer radiotherapy by use of fiducial markers. Acta Oncol 2019; 58: 943–50. doi: 10.1080/0284186X.2019.1588991
  36. Wu YW, Tseng PH, Lee YC, Wang SY, Chiu HM, Tu CH, et al. Association of esophageal inflammation, obesity and gastroesophageal reflux disease: From FDG PET/CT perspective. PLoS One 2014; 9: e92001. doi: 10.1371/journal.pone.0092001
DOI: https://doi.org/10.2478/raon-2024-0043 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 580 - 587
Submitted on: May 11, 2024
Accepted on: Jul 25, 2024
Published on: Oct 4, 2024
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2024 Ajra Secerov-Ermenc, Primoz Peterlin, Franc Anderluh, Jasna But-Hadzic, Ana Jeromen-Peressutti, Vaneja Velenik, Barbara Segedin, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.